カテゴリ： GlobalData, アメリカ, 企業調査

pSivida Corp (PSDV)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：pSivida Corp (PSDV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8013442
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月28日
◆ページ数：70
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
pSivida Corp (pSivida) is a specialty pharmaceutical company that offers development of miniaturized, sustained-release drug delivery products and technologies. The company’s products include iluvien, retisert and durasert. Its durasert is an injectable, miniaturized, sustained-release drug delivery system, used for the treatment of chronic diseases of the back of the eye. pSivida’s iluvien is an injectable, non-erodible, intravitreal implant for the treatment of DME. The company offers drug delivery products and technologies to treat serious, debilitating diseases of the eye that can lead to blindness. It operates in the US and the UK. pSivida is headquartered in Watertown, Massachusetts, the US.

pSivida Corp (PSDV) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
pSivida Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
pSivida Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
pSivida Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
pSivida Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
pSivida Corp, Medical Devices Deals, 2011 to YTD 2017 10
pSivida Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
pSivida Corp, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
pSivida and Nicox Enter into Agreement 12
pSivida Enters into Agreement with Major Global Pharmaceutical Company 13
Equity Offering 14
pSivida Plans to Raise Upto USD20 Million in Public Offering of Shares 14
pSivida Raises USD17.8 Million in Public Offering of Shares 15
pSivida Raises USD7 Million in Private Placement of Shares 17
pSivida Announces Private Placement Of Shares For US$19 Million 18
pSivida Completes Public Offering Of Shares For US$10.8 Million 19
pSivida Completes Private Placement Of Units For US$5.4 Million 20
pSivida Completes Registered Direct Offering Of Units For US$11 Million 21
pSivida Corp – Key Competitors 23
pSivida Corp – Key Employees 24
pSivida Corp – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Nov 07, 2017: pSivida Builds Momentum During First Quarter FY18; Continues Operating Milestone Execution 26
Sep 11, 2017: pSivida Achieves Significant Milestones Throughout FY 2017; Reports Fourth Quarter and Fiscal 2017 Results 27
May 04, 2017: pSivida Reports Fiscal 2017 Third Quarter Results; Key Milestones on Track 28
May 04, 2017: pSivida Reports Fiscal 2017 Third Quarter Results 29
May 04, 2017: pSivida Q3 net loss increases 30
Feb 07, 2017: pSivida Reports Fiscal 2017 Second Quarter and First Half Results 31
Nov 07, 2016: pSivida Reports Fiscal 2017 First Quarter Results and Provides Update on Corporate Objectives & Milestone Timeline 33
Sep 12, 2016: PSIVIDA Provides Company Update And Reports Fourth Quarter And FY 2016 Results 35
Feb 08, 2016: Psivida Provides Company Update And Reports Second Quarter FY 201 6 Results 37
Corporate Communications 39
Jun 28, 2017: pSivida Enhances Board of Directors with Election of Veteran Healthcare Executive Kristine Peterson 39
Sep 27, 2016: pSivida Strengthens Board of Directors With Leading Ophthalmologist 40
Aug 03, 2016: pSivida Names Dario Paggiarino, M.D. as Chief Medical Officer 41
Product News 42
10/26/2016: Alimera Sciences Begins Selling ILUVIEN in the Middle East 42
09/06/2016: Alimera Sciences Announces 23 Clinical Presentations and a Sponsored Symposium at 16th EURETINA Congress 43
08/09/2017: Alimera Sciences Announces Data to be Presented at the 2017 Annual ASRS Meeting 45
08/09/2016: Alimera Sciences announces clinical presentations and sponsored Symposia at ASRS 2016 Annual meeting 46
08/07/2017: Alimera Sciences CEO Dan Myers to Present U.S. Real-World ILUVIEN Post-Marketing Data During Ophthalmology Innovation Summit at ASRS, August 10, 2017 47
07/25/2017: Alimera Sciences Announces Real-World Audit Data Supporting the Positive Benefits of ILUVIEN Treatment 48
07/18/2017: Leading Retinal Specialists to Highlight pSivida’s Durasert for Treatment of Posterior Segment Uveitis at Prestigious Ophthalmology Conferences 49
07/17/2017: Real-world Data Reveal Real-world Benefits Of Iluvien Treatment 50
07/12/2017: Alimera Sciences Announces Italian Patients Now Being Treated With ILUVIEN 51
05/11/2016: Alimera Sciences’ ILUVIEN Data Presented at SFO 2016 52
05/06/2016: Alimera Sciences ILUVIEN Data Presented At 2016 ARVO 53
05/01/2017: Alimera Sciences Announces Data From 27 ILUVIEN Studies to Be Presented at 2017 ARVO 54
03/15/2017: Abstract on pSivida’s Treatment of Posterior Segment Uveitis Accepted for Presentation at the 2017 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 57
02/06/2017: Alimera Sciences Announces the Reimbursement of ILUVIEN in Italy 58
01/04/2016: Alimera Sciences Announces ILUVIEN J Code J7313 Is Now Active 59
Product Approvals 60
Feb 22, 2017: Alimera Sciences and Knight Therapeutics Announce Filing of New Drug Submission for Iluvien in Canada 60
May 02, 2016: pSividas Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe 61
Clinical Trials 62
Jul 19, 2017: Positive Results Enable Alimera Sciences to Reduce Enrollment in ILUVIEN Registry Safety Study in the U.K. 62
May 08, 2017: Durasert Three-year Treatment for Posterior Segment Uveitis Significantly Reduces Recurrences Through 12 Months 63
Oct 04, 2016: Phase 3 trial of Medidur in Posterior Segment Uveitis Meets Enrollment Target 64
Aug 15, 2016: Topline Results from First Phase 3 Trial of pSividas Medidur Presented at ASRS Annual Meeting 65
Aug 09, 2016: Primary Endpoint Met in pSivida’s Utilization Study of New Medidur Inserter with Smaller Diameter Needle 66
Jul 27, 2016: pSivida’s Medidur Maintains Same High Statistical Significance in Primary Endpoint through 12 Months in First Phase 3 Trial (p Less Than 0.00000001) 67
Jul 14, 2016: Investigator-Sponsored Phase 2 Study Results Show pSivida’s Medidur Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve 68
Mar 15, 2016: Additional Favorable Six-Month Safety Results for pSividas Medidur for Posterior Uveitis 69
Appendix 70
Methodology 70
About GlobalData 70
Contact Us 70
Disclaimer 70

List of Tables
pSivida Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
pSivida Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
pSivida Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
pSivida Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
pSivida Corp, Deals By Therapy Area, 2011 to YTD 2017 9
pSivida Corp, Medical Devices Deals, 2011 to YTD 2017 10
pSivida Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
pSivida and Nicox Enter into Agreement 12
pSivida Enters into Agreement with Major Global Pharmaceutical Company 13
pSivida Plans to Raise Upto USD20 Million in Public Offering of Shares 14
pSivida Raises USD17.8 Million in Public Offering of Shares 15
pSivida Raises USD7 Million in Private Placement of Shares 17
pSivida Announces Private Placement Of Shares For US$19 Million 18
pSivida Completes Public Offering Of Shares For US$10.8 Million 19
pSivida Completes Private Placement Of Units For US$5.4 Million 20
pSivida Completes Registered Direct Offering Of Units For US$11 Million 21
pSivida Corp, Key Competitors 23
pSivida Corp, Key Employees 24
pSivida Corp, Subsidiaries 25

★海外企業調査レポート[pSivida Corp (PSDV)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Targa Resources Corp (TRGP)：企業の財務・戦略的SWOT分析
    Targa Resources Corp (TRGP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Valaris Plc (VAL)：企業の財務・戦略的SWOT分析
    Valaris Plc (VAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • HomeWorks Tri-County Electric Cooperative Inc：企業の発電所・SWOT分析2018
    HomeWorks Tri-County Electric Cooperative Inc - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, in …
  • Emerson Electric Co (EMR)-エネルギー分野：企業M&A・提携分析
    Summary Emerson Electric Co. (Emerson) is a provider of infrastructure technologies and life cycle services for information and communication technology systems. The company offers hardware and software solutions for power, thermal and infrastructure management under the brands of Kop-Flex, jaure, a …
  • Iberia Lineas Aereas De Espana, Sa
    Iberia Lineas Aereas De Espana, Sa - Strategy, SWOT and Corporate Finance Report Summary Iberia Lineas Aereas De Espana, Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Glaukos Corp (GKOS)：企業の製品パイプライン分析2018
    Summary Glaukos Corp (Glaukos) is an ophthalmic medical device company that research and develops micro technologies to improve glaucoma therapy. The company develops injectable micro-scale therapies to address the complete range of glaucoma disease states and progression. It provides products such …
  • IDT Biologika GmbH：製薬・医療：M&Aディール及び事業提携情報
    Summary IDT Biologika GmbH (IDT Biologika), a subsidiary of Klocke Pharma-Service GmbH, is a vaccines and pharmaceuticals manufacturer. The company offers contract manufacturing services. It provides integrated development and manufacturing services in four major areas of animal health, vaccines, ph …
  • Simon Property Group, Inc.：企業のM&A・事業提携・投資動向
    Simon Property Group, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Simon Property Group, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • HeartWare International Inc：企業の戦略的SWOT分析
    HeartWare International Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Dairygold Co-operative Society Ltd：企業の戦略的SWOT分析
    Dairygold Co-operative Society Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Yihai International Holding Ltd (1579)：企業の財務・戦略的SWOT分析
    Yihai International Holding Ltd (1579) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • PACCAR Inc (PCAR)：企業の財務・戦略的SWOT分析
    PACCAR Inc (PCAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • HedgePath Pharmaceuticals Inc (HPPI)：製薬・医療：M&Aディール及び事業提携情報
    Summary Hedgepath Pharmaceuticals Inc (Hedgepath), a subsidiary of Mayne Pharma Group Ltd, is a clinical stage biopharmaceutical company that discovers, develops and commercializes novel therapeutics for the treatment of skin, prostrate, and lung cancers. The company is investigating an oral formula …
  • BellBrook Labs LLC-医療機器分野：企業M&A・提携分析
    Summary BellBrook Labs LLC (BellBrook) is a medical device company that develops detection reagents and screening tools. The company’s biochemical assay technology offers UVO microconduit array platform, chemotaxis assay plate, transcreener HTS assays, ADP² assays, AMP² and GMP² assays, GDP assays, …
  • RSWM Ltd. (RSWM)：企業の財務・戦略的SWOT分析
    RSWM Ltd. (RSWM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Mitsui E&S Holdings Co., Ltd. (7003)：石油・ガス：M&Aディール及び事業提携情報
    Summary Mitsui E&S Holdings Co., Ltd. (Mitsui E&S) is a shipbuilding and engineering product manufacturing company. It has diversified business operations comprising environment recycling, construction of social infrastructure, advanced machinery systems, IT-related activities, ships and oceans, pla …
  • Golden Grain Energy LLC：企業の戦略的SWOT分析
    Golden Grain Energy LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Nexstar Media Group, Inc. (NXST)：企業の財務・戦略的SWOT分析
    Nexstar Media Group, Inc. (NXST) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Integrated BioPharma Inc (INBP)：企業の財務・戦略的SWOT分析
    Summary Integrated BioPharma Inc (IBI) is a biopharmaceutical company that develops, manufactures and distributes vitamins, nutritional supplements and herbal products. The company’s contract business includes manufacturing, branded proprietary products, and other nutraceutical businesses. Its contr …
  • Global Partners LP：企業の戦略・SWOT・財務情報
    Global Partners LP - Strategy, SWOT and Corporate Finance Report Summary Global Partners LP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆